Biomarkers of GH action in children and adults

• Published in: Growth hormone & IGF research Vol. 40; pp. 1 - 8
• Main Authors: Schilbach, Katharina, Olsson, Daniel S., Boguszewski, Margaret C.S., Bidlingmaier, Martin, Johannsson, Gudmundur, Jørgensen, Jens-Otto Lunde
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01.06.2018
• Subjects: Acromegaly; Biomarker; Endocrinology and Diabetes; Endokrinologi och diabetes; GH treatment; Growth hormone; Growth hormone deficiency; IGF-I; Pediatrics; Pediatrik; Acromegaly; IGF-I; Biomarker; Growth hormone; GH treatment; Growth hormone deficiency
• ISSN: 1096-6374; 1532-2238
• DOI: 10.1016/j.ghir.2018.03.005

Growth hormone (GH) and IGF-I levels in serum are used as biomarkers in the diagnosis and management of GH-related disorders but have not been subject to structured validation. Auxological parameters in children and changes in body composition in adults, as well as metabolic parameters and patient related outcomes are used as clinical and surrogate endpoints. New treatment options, such as long acting GH and GH antagonists, require reevaluation of the currently used biochemical biomarkers. This article will review biomarkers, surrogate endpoints and clinical endpoints related to GH treatment in children and adults as well as in acromegaly. •GH & IGF-I are widely used as biomarkers in GH-related disorders although not structurally validated.•New treatments may require reevaluation of currently used biomarkers.•New biomarkers are also needed that more closely relate to clinical endpoints.•We review biomarkers and clinical endpoints in relation to GH treatment and acromegaly.